ADVERTISEMENT
Corrigendum: The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences
There are errors in the article by Davids et al, published in the June 2022 issue of the Journal of Clinical Pathways.1 First, the figure titles and legends provided were not associated with the correct figure images, and thus the figures appear with the wrong information and out of order. This error affected Figures 2-5 in the original version of the article but did not affect the data conveyed in these figures, the data in the article text, Figure 1, or Tables 1-3. Second, citations to two supplementary tables were missing from the final article and the supplementary material file was missing from the online article. Third, some minor typographical errors were corrected that do not affect the data but improve readability of the article.
For the convenience of our readers, the online version of the article has been updated so Figures 2-5 appear in the intended order with their correct titles and legends; the citations to the two supplementary tables appear in their correct locations and the supplementary material is available for readers to download; and the minor typographical errors are corrected.
References
1. Davids MS, Manzoor, BS, Hazra NC et al. The economic impact of treatment sequences for chronic lymphocytic leukemia in the United States: a cost of care and budget impact model of venetoclax plus obinutuzumab sequences. J Clin Pathways. 2022;8(5):36-46. doi:10.25270/jcp.2022.06.1
